Overview

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca
Maastricht University Medical Center

Treatments:

Anastrozole
Tamoxifen